Welcome to&nbsp;The Hematology Podcast, your source for the latest insights into hematology and rare blood disorders. This podcast covers cutting-edge research, clinical advancements, and real-world cases tailored for healthcare professionals. Each episode offers expert perspectives on evolving therapies and best practices, helping you stay informed and improve patient outcomes. Whether you're focused on research or clinical practice, The Hematology Podcast is designed to keep you at the forefront of the field, transforming your approach to hematology.​

Minimal residual disease (MRD) can today be evaluated in individual patient after treatment using various methods with high sensitivity. MRD indicates remaining malignant cells that could be a source of relapse of the disease. Could MRD also be used as an efficient endpoint in the design of new clinical studies? With help from Professor Ola Landgren, we will look into the crystal ball and discover what the future may hold for MRD.
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Ola Landgren, Professor of Medicine, Chief of Myeloma Program &amp; Experimental Therapeutics Program. Sylvester Comprehensive Cancer Center, University of Miami.
<h4>Expert guest</h4>

MRD as primary endpoint - Episode 5

Detection of Minimal Residual Disease (MRD) is becoming more important in different fields of hematology including Multiple Myeloma. Over the past decades we’ve been able to improve the sensitivity of detecting minimal levels of MRD through innovations in molecular biology. But should MRD always be treated? Will it give a better outcome for the patient? And do the benefits outweigh the costs?
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Dr Fredrik Schjesvold, head of the Oslo Myeloma Center.
<h4 class="exptguest">Expert guest</h4>

Minimal Residual Disease (MRD) - Cost vs Benefit - Episode 4

GAUCHER

RARE-DISEASE

One drop of blood, two sheets of glass, 40x objective. Hematological diagnostics demands a keen eye and sound reasoning. At the same time, artificial intelligence is entering the field in a big way. We ask: are the days of Giemsa coloring past us? What will machines be able to do for us, and is there a new role for humans in hematological diagnostics?​
Host for the podcast is the Swedish hematologist Mats Merup. Special guests in this episode are Birgitta Sander, basic researcher and pathologist, senior physician and professor at Karolinska Institute and Morten Goodwin, researcher and professor at the University of Agder in the field of artificial Intelligence.​
<h4 class="exptguest">Expert guest</h4>

Artificial Intelligence - The future of pathology? - Episode 3

We’re currently able to scan the entire human genome in a single day, and the application of genetic sequencing has the potential to improve diagnosis, prognosis and treatment. Ahead lies the opportunity to easily discover rare hematological diseases that might previously have gone unnoticed or would have been hard to diagnose. We look closer at genetic sequencing and discuss its applications.
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Professor Janna Saarela. Jaana is the director of the Norwegian Centre for molecular medicine, and a researcher working to improve our understanding of the disease pathogenesis and mechanisms of human immune disorder.
<h4 class="exptguest">Expert guest</h4>

It’s in the Genes - Episode 2

aTTP is a hematological disease so rare that all professionals struggle to identify it. In this episode, we talk to a hematologist who has diagnosed and treated a patient with aTTP, and we discover what actions a hematologist takes, when facing a deadly acute disease which has six incidents per million in a year.
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Henrik Frederiksen, Chief Physician, clinical associate professor, Phd, Department of Haematology X, Odense University Hospital and the Department of Clinical Research, University of Southern Denmark.
<h4 class="exptguest">Expert guest</h4>

aTTP - Episode 1

<h2>For additional insights and resources in hematology, refer to the following sites:​</h2>

Educational programs for healthcare professionals

Heeft u vragen of wilt u meer weten? Wij zorgen dat u zo snel mogelijk geholpen wordt.

Wij staan klaar

The Hematology Podcast - Season 1

Mental health includes our emotional, psychological and social well-being. A physical illness can have a severe impact on mental health. As health care professionals we often focus primarily on treatment and how to handle side effects and complications. The mental aspect of a disease is taking the back seat. How is mental health affected by a cancer diagnosis and treatment. And what does mental health mean for the patient's ability to cope with treatment and for the final outcome of treatment? And how is mental health affected after treatment is completed?
In this episode we have the pleasure of having Christoffer Johansen with us. He currently works at the Department of Oncology, Rigshospitalet in Denmark. Besides doing research in Oncology, Epidemiology and Clinical Trials, he has scientific focus on mental health for many years.
<h4 class="exptguest">Expert guest</h4>

Mental health during and after cancer treatment - Episode 8

In this episode we will discuss rare, inherited metabolic disorders in general, as well diseases such as Gaucher and other diseases. These genetic conditions are very rare. They can be diagnosed, after suspicion, by different screening test. But symptoms may vary greatly within these disorders and the road to an accurate diagnosis can therefore be challenging.
Guest in this episode is Professor Allan Lund. He is a board-certified specialist in pediatrics with expert training in rare pediatric metabolism. He currently works at Rigshospitalet in Copenhagen Denmark where he is the leader of Center for Rare metabolic diseases for children and adults. He has spent several years of research, diagnosing, and treating patients with different rare metabolic disorders.
<h4 class="exptguest">Expert guest</h4>

Challenges in diagnosing Gaucher and other rare inherited metabolic disorders - Episode 7

Hemoglobinopathies have previously been rare in the Nordic population but with increasing migration we now meet many patients with different types of thalassemias and hemoglobin variants. It is important to recognize these conditions and diagnosis can sometimes be challenging.
In this episode we will meet an expert in hemoglobin disorders who will discuss classification and diagnostic procedures. Britta Landin is associate professor and senior consultant at the Karolinska University Hospital in Stockholm. Host for the podcast is the Swedish hematologist Mats Merup.
<h4 class="exptguest">Expert guest</h4>

Hemoglobinopathies - Episode 6

The Hematology Podcast - Season 2

Today we will discuss a rare, inherited metabolic disorder known as ASMD, acid sphingomyelinase deficiency (or historically known as Niemann-Pick types A, A/B, and B). This genetic condition is very rare. It can be diagnosed, after suspicion, by different screening tests. But symptoms may vary greatly, overlap with several other disorders and the road to an accurate diagnosis can therefore be challenging.
In today’s episode we have the pleasure of welcoming Professor David Cassiman to the studio. He is a specialist in hepatology with profound knowledge of metabolic diseases. He currently works at the University Hospital of Leuven (Belgium) where he is the head of the Center for Hereditary Metabolic Diseases. He has spent several years of research, diagnosing, and treating patients with different rare metabolic disorders.
<h4 class="exptguest">Expert guest</h4>

Causes, Symptoms and Diagnosing ASMD – A rare genetic disorder - Episode 14

Monoclonal gammopathy of renal significance (MGRS) is a hemato-nephrological term referring to a heterogeneous group of kidney disorders characterized by direct or indirect kidney injury caused by a monoclonal immunoglobulin (MIg) produced by a B cell or plasma cell clone that does not meet current hematologic criteria for therapy. MGRS-associated kidney diseases are diverse and can result in the development of end stage kidney disease (ESKD).
In this episode we have the pleasure of having the Belgian Assistant professor Dr Amaryllis Van Craenenbroeck with us in the studio. She is Assistant professor at UZ Leuven and specialises in kidney transplantation and kidney diseases. She is board member of different research consortia and societies like for example Chair position in European Renal Association. Prof Van Craenenbroeck is also a frequent speaker at international scientific conferences. She will bring us up to date on recent understandings of the MGRS, how to diagnosed and what symptoms we as hematologists should be aware of.
<h4 class="exptguest">Expert guest</h4>

(MGRS) Monoclonal gammopathy of renal significance - Episode 13

Sickle cell disease (SCD) is a hereditary blood disorder, where red blood cells have the shape of a C or sickle - hence the name. Sickle cells have a shorter lifespan than normal red blood cells, which causes anemia. Additionally, sickle cells may block blood vessels, especially during infections, dehydration, stress or fatigue, causing complications for the patients.
Our guest today Professor Bart Biemond is a hematologist at the Amsterdam UMC in The Netherlands. He is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations. His efforts in research have led among others to greater understanding of biomarkers in SCD and complications associated with this disease. In this episode of our Hematology Podcast, Bart will tell us more about SCD, its clinical implications and developments in research which implicate patients today and in the future.
<h4 class="exptguest">Expert guest</h4>

Sickle cell disease - A hereditary blood disorder - Episode 12

Extramedullary disease (EMD) represents an aggressive form of multiple myeloma, characterized by the ability of myeloma cells to form tumors outside the bone marrow independently. Scientific research is continuously evolving, leading to discoveries of new treatments and improvements to current options. However, EMD remains challenging from a therapeutic and biological perspective, and today the prognosis for patients with the disease is generally poor. Experts call for a better understanding of how myeloma cells grow and thrive and about the biology of extramedullary tumors to develop better treatment strategies for the future.
Dr. Elena Zamagni is an expert in this area, and our guest in this episode, all the way from Italy. Dr. Zamagni is an associate professor at the Department of Medical and Surgical Sciences at the University of Bologna and has been a principal investigator in several national and international clinical trials in multiple myeloma.
<h4 class="exptguest">Expert guest</h4>

Extramedullary disease in Multiple Myeloma - Episode 11

Monoclonal gammopathy of undetermined significance, called MGUS, is a blood condition which indicates occurrence of clonal cells that secrete monoclonal immunoglobulins. MGUS as such, is not a harmful disease, and usually doesn’t require treatment. However, every year 1 percent of MGUS patients go on to develop myeloma or lymphoma.
In this episode we have the pleasure of having the Icelandic Professor Sigurdur Kristinsson with us. He specializes in internal medicine and hematology. He has led several large population-based myeloma studies in collaboration with major research centers and is a frequent speaker at international hematology conferences. Professor Kristinsson will bring us up to date on recent understandings of the MGUS condition, what symptoms we as health care professionals should be aware of and how to diagnose today – and what could be possible in the future.
<h4 class="exptguest">Expert guest</h4>

Recent findings in MGUS - Episode 10

Waldenström Macroglobulinemia is a rare type of non-Hodgkin lymphoma affecting B-cells. Waldenström Macroglobulinemia is characterised by high levels of circulating antibodies, immunoglobulin M, which is made and secreted by the cells involved in the disease. It is usually an indolent disease with no or limited symptoms. Therefore, patients with Waldenström Macroglobulinemia are often follow closely in “Watchful Waiting” until the disease and symptoms require onset of treatment.
Our guest Ida Bruun Kristensen, hematologist at Odense University Hospital. Ida is an active member in both the Danish Lymphoma Group and Danish Myeloma Study Group as the active in the Nordic clinical societies and is responsible for several ongoing clinical studies. In this episode of our Haematology Podcast Ida enlighten us on Waldenström Macroglobulinemia, its clinical implications and treatment options for the patients today and in the future.
<h4 class="exptguest">Expert guest</h4>

Waldenström makroglobulinemi - Episode 9

The Hematology Podcast - Season 3

In this episode of The Hematology Podcast, we will delve into the complex world of thrombotic microangiopathy, or TMA. This condition encompasses a group of disorders characterized by small blood clots forming in the smallest blood vessels, leading to various complications. Diagnosing TMA can be particularly challenging due to its overlapping symptoms with other conditions and the need for specialized tests.
In today’s episode, we have the honor of welcoming Professor Riitta Lassila to the studio. Professor Lassila is a renowned expert in hematology with extensive experience in researching and treating TMA. She currently serves at the Helsinki University Hospital in Finland, where she leads the Hemostasis and Thrombosis Research Unit. Her groundbreaking work has significantly advanced our understanding of TMA and its management.
<h4 class="exptguest">Expert guest</h4>

TMA or Thrombotic microangiopathy - from Symptoms to Treatment - Episode 20

In this episode, we dive into the fascinating world of liquid biopsy-derived DNA as a revolutionary tool for comprehensive mutation profiling in multiple myeloma. This innovative approach offers a non-invasive way to analyze genetic alterations, potentially transforming how we diagnose and monitor this complex hematological cancer. Join us as we explore the promises and challenges of using liquid biopsies to decode the genetic landscape of multiple myeloma and its implications for personalized medicine.
We have the pleasure of welcoming Dr. Wouter De Brouwer from Belgium to our studio. Dr. De Brouwer is a hematologist in training and PhD student at the hematology and immunology research group (HEIM) from the faculty of Brussels health campus, with a special interest in genomic profiling in hematological malignancies. Join us as Dr. De Brouwer sheds light on the potential of liquid biopsies to revolutionize personalized medicine and improve patient outcomes.
<h4 class="exptguest">Expert guest</h4>

Decoding Multiple Myeloma genetic profile: The Power of Liquid Biopsy-Derived DNA - Episode 19

In this episode, we focus on Thalassemia major, a severe form of the disease. In a previous episode, we discussed Thalassemia minor and intermedia with Professor Dr. Bart Biemond from Amsterdam UMC. Now, we will delve deeper into the challenges and treatments associated with Thalassemia major. Prof. Biemond is still with us to share his expertise.
Professor Bart Biemond is a hematologist at the Amsterdam UMC in The Netherlands. Bart is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations.
<h4 class="exptguest">Expert guest</h4>

Transfusion Dependent Thalassemia - the Severe Spectrum - Episode 18

Acute myeloid leukemia (AML) is a hematopoietic stem cell-derived myeloid malignancy characterized by manifold genetic aberrations and poor overall survival. Standard treatment for newly diagnosed fit AML patients is intensive chemotherapy. Relapse is, however, a challenge in more than 40% of AML patients. AML is also a disease with a large degree of individual heterogeneity, which creates challenges both for diagnostics and for developing targeted treatment options.
Our guest is Björn Gjertsen, professor of hematology at the University of Bergen, Norway. Björn is also part of Centre for Cancer Biomarkers, CCBIO, and founding member and chair of the Nordic AML group and member of HOVON AML International Steering Group. He has extensive experience in treating AML, in clinical and translational research of AML, including very exciting newly published data on how single cell signalling profiling may help to detect responders and non-responders early in the treatment.
<h4 class="exptguest">Expert guest</h4>

AML - from basics to future prospectives - Episode 17

Smoldering multiple myeloma (SMM) is an intermediate condition that lies between Monoclonal gammopathy of undetermined significance (MGUS) and active multiple myeloma along the spectrum of clonal plasma cell proliferative disorders. Smoldering multiple myeloma may take years to become active multiple myeloma. In some cases, people who have this condition never develop active multiple myeloma.
In this episode we have the pleasure of having the Norwegian haematologist Fredrik Schjesvold with us. Fredrik is the founder and leader of Oslo Myeloma Center at Oslo University Hospital. Fredrik is an international expert on Multiple Myeloma in charge of one of Europe’s largest centres for clinical research in this disease. He is also chairman of the Nordic Myeloma Study Group and leads the Norwegian Myeloma Group. Besides he is member of the International Myeloma Working Group, and board member of the European Myeloma network (EMN).
<h4 class="exptguest">Expert guest</h4>

Smoldering Multiple Myeloma – to treat or not to treat? - Episode 16

Thalassemia is a hereditary blood disorder, in which the synthesis of hemoglobin chains is impaired. Consequently, people with thalassemia minor may have slight to severe anemia which usually does not cause any problems. Thalassemia major in contrast is a severe disorder with need of transfusion and complications with iron overload. In this episode we will mainly discuss thalassemia minor and intermedia.
Our guest today Professor Bart Biemond is a hematologist at the Amsterdam UMC in The Netherlands. Bart is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations. Today, Bart will tell us more about thalassemia, its clinical implications and developments in research which implicate patients today and in the future.
<h4 class="exptguest">Expert guest</h4>

Thalassemia a blind spot - Episode 15

The Hematology Podcast - Season 4

Voor uw intercontext, meld u aan bij uw account Sanofi Campus. Geef uw e-mail door aan uw e-mail.

Als u onze eerste e-mail op {email} tot bevestig uw account u kunt hieronder een nieuwe aanvragen. Als je het niet ziet, moet je mogelijk je spammap controleren.

Deze informatie wordt alleen gebruikt om uw account te valideren en wordt niet verspreid.

titel

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

Om u een gepersonaliseerde ervaring te bieden, moet u

Je profiel is onvolledig

De ADCT geeft een indicatie van hoe gecontroleerd het eczeem is. Beantwoord deze 6 eenvoudige vragen met uw patiënt om de ADCT-score te vinden. Het zal de juiste handelwijze aangeven.

Atopische dermatitis, een vorm van eczeem, kan het leven van uw patiënt op meer manieren beïnvloeden dan u weet.

Doe de atopische dermatitis controle test (ADCT)

Geniet van meer exclusieve inhoud{newline}door <a>door u vandaag te registreren</a>

Heb je al een account? <a>Hier inloggen</a>

Best practices voor het optimaliseren van de patiëntenzorg

Krijg een aangepast beeld van de onderwerpen waarin u geïnteresseerd bent, samen met de mogelijkheid om inhoud op te slaan om op een later tijdstip te bekijken of te lezen.

Onbeperkte toegang tot eersteklas inhoud, whitepapers, casestudy's, onderzoekspapers, webinars, training en up-to-date wetenschappelijke medische bronnen.

Gepersonaliseerde inhoud op basis van uw interessegebieden

Maak contact en blijf up-to-date met collega's op uw vakgebied en onderwerpen die u interesseren via gratis evenementen en leidinggevende forums.

Registreer om het volledige artikel te lezen.

Wij respecteren uw privacy en zullen uw informatie niet delen met derden.

Actuele gidsen die speciaal voor patiënten zijn geschreven

Onbeperkte toegang tot de nieuwste patiëntengidsen en bronnen. Deel inhoud met uw patiënten met gebruiksvriendelijke online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Beperkte toegang

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

Normaal gesproken bieden we een schat aan kenis, maar we konden niet vinden waar je naar op zoek bent.

We konden niet vinden wat je zocht

Sanofi is niet verantwoordelijk voor de inhoud van deze externe website.

U staat op het punt Campus.sanofi/nl te verlaten.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Volg ons:

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your QFITLIA Representative or receive updates about QFITLIA. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een lijst met evenementen en tools en diensten voor uw dagelijkse praktijk.

Bevestig uw status

De inhoud van deze website is alleen toegankelijk voor geregistreerde gebruikers.

Log in alstublieft

Email verificatie

U ziet een voorbeeld van de portal. Wis uw cookies (bijvoorbeeld door uw browservenster te sluiten) om terug te gaan naar de openbare modus.

We hebben onze privacyverklaring bijgewerkt om je gegevens beter te beschermen en je ervaring te verbeteren. Neem even de tijd om de wijzigingen door te nemen door <privacyNewTab>hier te klikken</privacyNewTab>. Uw privacy is belangrijk voor ons. Klik op doorgaan om te bevestigen dat u de nieuwe privacyverklaring hebt gelezen.

Update van de privacyverklaring

Communicatie toestemming

My consents

Password

Confirm password

{resultsCount, plural, one {resultaat} other {resultaten}}

Log in om toegang te krijgen tot de resultaten

U moet inloggen op uw account om toegang te krijgen tot medische inhoud.

Inloggen

Registreer in minder dan 1 minuut om toegang te krijgen tot de resultaten

U verlaat nu het Sanofi inhoudsgedeelte van onze site en komt in het inhoudsgedeelte voor extern medisch bibliografisch zoeken.

U verlaat nu het externe medische bibliografische zoekgedeelte van onze site en komt in het inhoudsgedeelte van Sanofi.

Gaucher

Educatie

The Hematology Podcast - Season 1

The Hematology Podcast - Season 2

The Hematology Podcast - Season 3

The Hematology Podcast - Season 4